Advances in Technology for SMILE procedure

In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.

Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.

Two investigational pipeline therapies take aim at the root causes of dry eye disease

The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.

Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.

Length and width, not thickness, emerge as key drivers of higher-order aberrations.

What the approval of a second targeted biologic means for patients, practice, and the evolving TED treatment landscape

Three real-world cases illustrate strategies to identify and manage GA across a range of scenarios, from coexisting wet age-related macular degeneration to functionally monocular patients.